LY2603618(IC-83) is a potent and selective small molecule inhibitor of Chk1 protein kinase activity in vitro (IC50=7 nM) and the first selective Chk1 inhibitor to enter clinical cancer trials.
For research use only. We do not sell to patients.
Name | Rabusertib(LY2603618) |
---|---|
Iupac Chemical Name | (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea |
Synonyms | LY2603618; LY 2603618; LY-2603618; Rabusertib |
Molecular Formula | C18H22BrN5O3 |
Molecular Weight | 436.3 |
Smile | Cc1cc(c(cc1Br)NC(=O)Nc2cnc(cn2)C)OC[C@@H]3CNCCO3 |
InChiKey | SYYBDNPGDKKJDU-ZDUSSCGKSA-N |
InChi | InChI=1S/C18H22BrN5O3/c1-11-5-16(27-10-13-8-20-3-4-26-13)15(6-14(11)19)23-18(25)24-17-9-21-12(2)7-22-17/h5-7,9,13,20H,3-4,8,10H2,1-2H3,(H2,22,23,24,25)/t13-/m0/s1 |
CAS Number | 911222-45-2 |
MDL | MFCD18633253 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Purity | 98% |
---|---|
Solubility | DMSO ��20mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL |
Handling | |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |
1. Compositions of Chk1 kinase inhibitor for cancer treatment By Colvin, Anita A.; Koppenol, Sandy; Wisdom, Wendy A. From PCT Int. Appl. (2008), WO 2008067027 A2 20080605.